Equities Analysts Offer Predictions for STOK FY2025 Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Stoke Therapeutics in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan forecasts that the company will post earnings of ($2.40) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.03) per share.

Other equities analysts have also issued reports about the stock. Chardan Capital began coverage on shares of Stoke Therapeutics in a research report on Friday, December 20th. They set a “buy” rating and a $24.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, January 8th. Needham & Company LLC restated a “buy” rating and set a $22.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, January 8th. Leerink Partners started coverage on Stoke Therapeutics in a report on Monday, October 14th. They issued an “outperform” rating and a $18.00 price target on the stock. Finally, Leerink Partnrs raised Stoke Therapeutics to a “strong-buy” rating in a report on Friday, October 11th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $21.29.

Stoke Therapeutics Trading Up 4.7 %

Shares of NASDAQ STOK opened at $9.80 on Wednesday. Stoke Therapeutics has a 12-month low of $4.09 and a 12-month high of $17.58. The firm’s 50-day simple moving average is $11.40 and its 200 day simple moving average is $12.87.

Stoke Therapeutics (NASDAQ:STOK) last announced its earnings results on Tuesday, November 5th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.05. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The company had revenue of $4.89 million for the quarter, compared to analysts’ expectations of $3.46 million.

Insider Transactions at Stoke Therapeutics

In other Stoke Therapeutics news, General Counsel Jonathan Allan sold 13,666 shares of the business’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $13.61, for a total value of $185,994.26. Following the completion of the transaction, the general counsel now directly owns 21,476 shares of the company’s stock, valued at approximately $292,288.36. The trade was a 38.89 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Barry Ticho sold 13,945 shares of Stoke Therapeutics stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $12.78, for a total value of $178,217.10. Following the transaction, the insider now owns 47,332 shares in the company, valued at $604,902.96. This trade represents a 22.76 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 62,849 shares of company stock worth $809,421. 11.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Stoke Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. The Manufacturers Life Insurance Company boosted its stake in Stoke Therapeutics by 16.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock worth $189,000 after purchasing an additional 1,994 shares during the period. Rhumbline Advisers boosted its position in shares of Stoke Therapeutics by 14.3% during the second quarter. Rhumbline Advisers now owns 47,860 shares of the company’s stock worth $647,000 after buying an additional 5,990 shares during the period. Intech Investment Management LLC bought a new position in shares of Stoke Therapeutics during the third quarter worth about $160,000. Profund Advisors LLC bought a new position in shares of Stoke Therapeutics during the second quarter worth about $201,000. Finally, Mesirow Financial Investment Management Inc. acquired a new position in Stoke Therapeutics during the 3rd quarter worth approximately $192,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.